SMARCA4 and ovarian neoplasm: We aimed to evaluate the clinical utility of SMARCA4 IHC testing among a large cohort of centrally reviewed SCCOHT (N = 44) and other rare ovarian tumours occurring in young women and frequently misdiagnosed as SCCOHT (N = 94).